Mara Goldstein
Stock Analyst at Mizuho
(2.69)
# 1,885
Out of 4,853 analysts
77
Total ratings
43.1%
Success rate
5.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $6.57 | +356.62% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $1.80 | +455.56% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $6.18 | +29.45% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $9.63 | +336.14% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $9.12 | +448.25% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $11.16 | +303.23% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $67.24 | +14.52% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.58 | +344.44% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.34 | +497.01% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.40 | +2,936.44% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.67 | +789.15% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $3.91 | -10.49% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.12 | +9,891.67% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $2.05 | +875.61% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $77.62 | +67.48% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $2.40 | -16.67% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.26 | +430.97% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.29 | +3,047.95% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $32.08 | -37.66% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.40 | +548.65% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.53 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $3.64 | +284.62% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $6.57
Upside: +356.62%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $1.80
Upside: +455.56%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.18
Upside: +29.45%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $9.63
Upside: +336.14%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $9.12
Upside: +448.25%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $11.16
Upside: +303.23%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $67.24
Upside: +14.52%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.58
Upside: +344.44%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.34
Upside: +497.01%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.40
Upside: +2,936.44%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.67
Upside: +789.15%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $3.91
Upside: -10.49%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.12
Upside: +9,891.67%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $2.05
Upside: +875.61%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $77.62
Upside: +67.48%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $2.40
Upside: -16.67%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.26
Upside: +430.97%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.29
Upside: +3,047.95%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $32.08
Upside: -37.66%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.40
Upside: +548.65%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $19.53
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $3.64
Upside: +284.62%